Dartmouth: Researchers Find a New Therapeutic Target in Pancreatic Cancer
July 30, 2020
July 30, 2020
DARTMOUTH, New Hampshire, July 30 -- The Dartmouth College Geisel School of Medicine issued the following news release:
The development of pancreatic cancer is driven by co-existing mutations in an oncogene involved in controlling cell growth, called KRAS, and in a tumor suppressor gene, called p53. But how these mutations cooperate to promote cancer is unknown. A new study co-led by Steven Leach, MD, Director of Dartmouth's and Dartmouth-Hitchcock's Norris Cotton Cancer C . . .
The development of pancreatic cancer is driven by co-existing mutations in an oncogene involved in controlling cell growth, called KRAS, and in a tumor suppressor gene, called p53. But how these mutations cooperate to promote cancer is unknown. A new study co-led by Steven Leach, MD, Director of Dartmouth's and Dartmouth-Hitchcock's Norris Cotton Cancer C . . .